Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > Sugemalimab offers PFS benefits for unresectable NSCLC

Sugemalimab offers PFS benefits for unresectable NSCLC

Presented By
Prof. Yi-Long Wu, Guangdong Provincial People’s Hospital, China
WCLC 2022
Phase 3, GEMSTONE-301
The final progression-free survival (PFS) analysis of the phase 3 GEMSTONE-301 trial demonstrated clinical benefits for patients with unresectable stage III non-small cell lung cancer (NSCLC) who were treated with sugemalimab after chemotherapy compared with those receiving placebo after chemotherapy. According to the investigators, sugemalimab presented itself as a new standard-of-care for the inoperable NSCLC population [1]. The phase 3 GEMSTONE-301 trial (NCT03728556) compared the efficacy of the PD-L1 inhibitor sugemalimab (n=255) with placebo (n=126) in patients with stage III, unresectable NSCLC who did not progress after either concurrent or sequential chemoradiotherapy (CRT). Sugemalimab displayed a significant PFS benefit over placebo in the pre-planned interim PFS analysis [2]. At the WCLC 2022, Prof. Yi-Long Wu (Guangdong Provincial Peop...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on